We expect increased LINZUS U.S. net sales and our continued disciplined expense management to drive greater than $300 million in adjusted EBITDA in 2026, which will enable us to continue to advance apiglutide and reduce our debt to further strengthen our financial position.

Feb 25, 2026 / CEO / receipt, needs a key / Tom McCourt, CEO | earnings call 2026-02-25 | transcript faa2f042-f5fe-4a60-80db-765e1b0fb531 | chars 4699-4973 | segment 4

As such, our priorities in 2026 are clear. We'll continue to maximize LINZUS, we'll advance apraglutide by initiating SARS-2 for short bowel syndrome patients with intestinal failure, and we'll continue to emphasize disciplined expense management to deliver profits and meaningful cash flows, which will enable us to reduce our debt and further strengthen our financial position.

Feb 25, 2026 / CEO / receipt, needs a key / Tom McCourt, CEO | earnings call 2026-02-25 | transcript faa2f042-f5fe-4a60-80db-765e1b0fb531 | chars 4974-5353 | segment 4